Login / Signup

Quality-of-life scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: An analysis of the HIDIT-II trial.

Katja DinkelborgJulia KahlhöferPetra DörgeCihan YurdaydinSvenja HardtkeFlorin Alexandru CaruntuManuela G CurescuKendal YalcinUlus S AkarcaSelim GürelStefan ZeuzemAndreas ErhardtStefan LüthGeorgios PapatheodoridisOnur KeskinKerstin PortMonica RaduMustafa K CelenRamazan İdilmanKristina WeberJudith StiftUlrike WittkopBenjamin HeidrichIngmar MederackeHeiko von der LeyenHans Peter DienesMarkus CornbergArmin KochMichael P MannsHeiner WedemeyerKatja Deterdingnull null
Published in: Liver international : official journal of the International Association for the Study of the Liver (2023)
Overall, our findings suggest that PEG-IFNa-2a was reasonably tolerated even over a period of 96 weeks by hepatitis D patients reporting SF-36 questionnaires. Of note, several patients may benefit from PEG-IFNa-2a-based therapies with off-treatment improvements in quality of life.
Keyphrases
  • end stage renal disease
  • chronic kidney disease
  • ejection fraction
  • newly diagnosed
  • drug delivery
  • clinical trial
  • peritoneal dialysis
  • patient reported outcomes
  • study protocol
  • emergency department
  • adverse drug